Thirty Years of Free Therapy: Sanofi's Rare Humanitarian Program - Life Sciences Today Podcast Ep 62

Why It Matters

By delivering life‑saving therapies to underserved populations, Sanofi not only fulfills a humanitarian mandate but also strengthens its brand equity and market foothold in the growing rare‑disease sector.

Key Takeaways

• Sanofi’s Rare Humanitarian Program has treated over 4,000 patients worldwide.
• Digital “cyber‑grants” platform reduces case review to under 48 hours.
• Local medical expert committees build diagnostic and treatment capacity in emerging markets.
• Partnerships with NGOs streamline product logistics to underserved regions.
• Program showcases corporate responsibility while reinforcing Sanofi’s rare‑disease leadership.

Summary

The Life Sciences Today podcast highlighted Sanofi’s Rare Humanitarian Program, now in its 35th year, which provides free access to its orphan‑drug portfolio for patients in countries without commercial availability.

Since its 1991 launch, the initiative has served more than 4,000 individuals across 70 nations, with a peak of 1,250 patients in a single year. A new digital “cyber‑grants” portal lets physicians submit standardized applications, enabling case assessment in under 48 hours and often within hours.

Bunny Anderson explained how the program leverages local medical expert committees in India, Egypt and China to train physicians, improve diagnostics and monitor therapy, while NGOs such as Project Hope handle on‑the‑ground logistics—illustrated by a 36‑hour turnaround for a Ugandan patient.

The effort reinforces Sanofi’s reputation as a leader in rare‑disease treatment, creates a sustainable infrastructure for future patients, and demonstrates how corporate philanthropy can align with long‑term business strategy.

Original Description

We're excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Bonnie Anderson, Head of Humanitarian Programs, Rare Diseases at Sanofi. For more than 30 years, Sanofi's Rare Humanitarian Program has provided free enzyme replacement therapy to patients with lysosomal storage disorders — Gaucher, Fabry, Pompe, ASMD, MPS I and II — in countries where no reimbursement pathway exists. What started in 1991 with a single drug for a single disease has grown to cover six diseases across 100+ countries, with more than 3,600 patients treated and over 1,000 patients active today.

In this conversation we talk about what it actually takes to sustain patient access at this scale: how a physician in a country with no reimbursement initiates a request, how the program builds local diagnostic and treating capacity alongside the drug donation, and what changed in 2023 when Sanofi moved the review and approval workflow off spreadsheets and onto Bonterra's grants management platform — cutting approval turnaround to under 36 hours. We also talk about what three decades of humanitarian access have taught Sanofi about running programs that outlast portfolio changes, M&A, and generational staff turnover.

For more great episodes of our Life Sciences Today Podcast, check out: https://www.healthcareittoday.com/category/life-sciences-today-podcasts/